Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology

Miles, Kenneth, McQueen, Liam, Ngai, Stanley and Law, Phillip (2015) Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology. Cancer Imaging, 15 18: 1-8. doi:10.1186/s40644-015-0053-1

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Miles, Kenneth
McQueen, Liam
Ngai, Stanley
Law, Phillip
Title Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology
Journal name Cancer Imaging   Check publisher's open access policy
ISSN 1470-7330
Publication date 2015-11-17
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1186/s40644-015-0053-1
Open Access Status DOI
Volume 15
Issue 18
Start page 1
End page 8
Total pages 8
Place of publication London, United Kingdom
Publisher BioMed Central
Language eng
Abstract Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) is a hybrid of two technologies each with its own evidence for clinical effectiveness. This article amalgamates evidence for clinical effectiveness of fluorodeoxyglucose (FDG) PET/CT and MRI as separate modalities with current evidence for hybrid PET/MRI and considers whether such an approach might provide a stronger case for the clinical use of PET/MRI at an earlier stage. Because links between diagnostic accuracy and health outcomes have already been established for FDG-PET/CT in the investigation of suspected residual or recurrent malignancies, evidence showing improved diagnostic performance and therapeutic impact from the use of PET/MRI as an alternative would imply clinical effectiveness of this modality for this application. A meta-analysis of studies comparing FDG-PET/CT to MRI in patients with suspected residual disease or recurrence of tumours indicates complementary roles for these modalities. PET demonstrates greater sensitivity for recurrence within lymph nodes whereas MRI is more effective that PET/CT in the detection of skeletal and hepatic recurrence. A review of studies assessing therapeutic impact of PET/MRI suggests a greater likelihood for change in clinical management when PET/MRI is used for assessment of suspected residual or recurrent disease rather than tumour staging. Supplementing the evidence-base for FDG-PET/MRI with studies that compare the components of this hybrid technology deployed separately indicates that FDG-PET/MRI is likely to be clinical effective for the investigation of patients with a range of suspected residual or recurrent cancers. This indication should therefore be prioritised for further health technology assessment.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 Dec 2015, 04:52:06 EST by Phillip Law on behalf of Scholarly Communication and Digitisation Service